ReviewKidney international reports2023
Molecular Mechanisms of Rhabdomyolysis-Induced Kidney Injury: From Bench to Bedside.
Review in Kidney international reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 1 synthesis or guideline pooled it, 60 citations in OpenAlex.
- CDK4/6 inhibitor-statin interaction and rhabdomyolysis in breast cancer treatment: a case-based systematic review.Cancer chemotherapy and pharmacology · 2026Pooled it
- Review
- Early Hemolysis, Myolysis and Renal Stress Following Pentaspline Pulsed Field Versus Radiofrequency Ablation of Atrial Fibrillation.European journal of clinical investigation · 2026Observational
- Review
- Factors associated with acute kidney injury in rhabdomyolysis: Insights from a prospective study.World journal of nephrology · 2026Article
- Critical care considerations in rhabdomyolysis-associated acute kidney injury and kidney replacement therapy.World journal of nephrology · 2026Review
- A natural remedy: Kidney-targeting nanoplatform for photoacoustic imaging-guided three-in-one theranostics of rhabdomyolysis-induced acute kidney injury.Materials today. Bio · 2026Article
- Review
- L-carvone protects against myoglobinuric acute tubular necrosis via inhibition of NF-κB and caspase-dependent apoptotic pathways.Toxicology reports · 2026Article
- Isolation and functional characterization of primary human proximal tubular epithelial cells from brain-dead organ donors.Physiological reports · 2026Article
- Cast nephropathy in the ICU: Early recognition and extracorporeal strategies to improve outcomes.Journal of intensive medicine · 2026Review
- Article
- Rhabdomyolysis in a patient with lung cancer with sintilimab-induced overlap syndrome and hypothyroidism: A case report.Experimental and therapeutic medicine · 2026Article
- Efficacy of cilastatin sodium in a translational large animal crush syndrome model.Communications medicine · 2026Article
- Oxidative Stress in Heat Stress Nephropathy: Crosstalk.Oxidative medicine and cellular longevity · 2026Review
- Crocins ameliorate acute kidney injury in glycerol-induced rhabdomyolysis by targeting the PLIN1/PPARs signaling pathway.Frontiers in pharmacology · 2026Article
- Extracorporeal Blood Purification (HA-380) in Rhabdomyolysis-Induced Acute Kidney Injury: A Successful Outcome.European journal of case reports in internal medicine · 2026Article
- Renoprotective effects of human L-type fatty acid-binding protein (hL-FABP) in rhabdomyolysis-induced acute kidney injury.Scientific reports · 2025Article
- Hemoadsorption therapy in severe rhabdomyolysis: a report from the international, prospective COSMOS (CytOSorbRenal failure · 2025Observational
- Impact of COVID-19 on Renal Function: Analysis of Acute Kidney Injury Across Three Pandemic Waves.Biomedicines · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Rhabdomyolysis-induced acute kidney injury (RIAKI) occurs following damage to the muscular sarcolemma sheath, resulting in the leakage of myoglobin and other metabolites that cause kidney damage. Currently, the sole recommended clinical treatment for RIAKI is aggressive fluid resuscitation, but other potential therapies, including pretreatments for those at risk for developing RIAKI, are under investigation. This review outlines the mechanisms and clinical significance of RIAKI, investigational treatments and their specific targets, and the status of ongoing research trials.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.